HHS Releases Cost Savings For 54 Prescriptions Including Cancer Drug

The Biden administration is once again trumpeting the Medicare Prescription Drug Inflation Rebate Program to prove to voters it is lowering drug prices.

Through the program, 54 drugs will be less expensive for Medicare enrollees because of a lower Part B coinsurance rate from Oct. 1 through the end of the year. This is because drug companies raised the price of these 54 drugs faster than the rate of inflation, affecting 822,000 beneficiaries.

“The President’s lower cost prescription drug law continues to put money back in the pockets of seniors and people with disabilities,” said Department of Health and Human Services (HHS) Secretary Xavier Becerra in a statement. “President Biden and Vice President Harris promised to lower prescription drug costs—and they have delivered.”

The program has been in effect since April 2023. Each quarter, a new selection of drugs is discounted through the Inflation Reduction Act. This time, the program could could save patients $3,000 on the drug Kymriah, which treats cancer, the administration said.

Other drugs included in this round are Briumvi for multiple sclerosis, Krystexxa for chronic gout and Tivdak used to treat cervical cancer.

It is expected enrollees could save as much $3,854 depending on the prescription drug they need.

HHS discounted drugs for bladder cancer, osteoporosis, infections and more this year. Starting next year, Medicare Part D enrollees will have a $2,000 cap on annual out-of-pocket prescription drug costs.

In August, the feds announced savings on 10 prescription drugs through the drug negotiation program, which drastically reduces the price of drugs like Enbrel, Jardiance and Januvia, starting in 2026. A new list for negotiation in 2027 will be announced in February.

The Centers for Medicare & Medicaid Services will start invoicing prescription drug companies for rebates owed to Medicare by fall 2025. These rebates are deposited to the Federal Supplementary Medical Insurance Trust Fund.

 

Source Link

Recommended Articles

State PBM laws Face ERISA Preemption Challenges in Court

States seeking to limit the power of pharmacy benefit managers are running into legal roadblocks. Every state, as well as the federal government, has enacted PBM legislation over the last decade to rein in an industry accused of anticompetitive business practices. Those efforts have seen mixed results as agencies struggle to enforce requirements and courts ...

Read More

Employer Health Cost Crunch Is Worse Than Projected

There’s new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing ...

Read More

HHS Finalizes Changes To HIPAA Privacy Rule

HHS' Office for Civil Rights finalized a HIPAA privacy rule change cutting the protected health information request response window to 15 calendar days. The final regulation clarifies individuals can retrieve electronic PHI through health apps when entities can support that format.

Read More

Sutter Health-Allina Health Deal Clears Key Hurdle

Sutter Health and Allina Health have achieved a milestone in their plan to merge. The health systems agreed to invest $2.15 billion as part of a 10-year oversight arrangement that Minnesota Attorney General Keith Ellison (D) announced Monday. The deal has been under state review for months. Under terms of the agreement, Sacramento, California-based Sutter ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square